Search for the latest oncology news by tumour type
TAR-200 monotherapy demonstrates highest complete response rate reported to date with sustained clinical benefits in patients with certain types of bladder cancer
New data from Cohort 2 of the Phase 2b SunRISe-1 study evaluating TAR-200—an intravesical gemcitabine…